Our study demonstrates that upregulated METTL3 is associated with metastasis in vitro and in vivo through regulating the expression of miRNA-1246, which further suppress the expression of anti-oncogene SPRED2, thus providing a novel therapeutic target in CRC. Here, SPRED2 is linked to colorectal carcinoma.